Page 11 - Biodesix Nodify Lung News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biodesix nodify lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biodesix Nodify Lung Today - Breaking & Trending Today

Zacks: Brokerages Expect Biodesix, Inc. (NASDAQ:BDSX) Will Post Quarterly Sales of $6.88 Million

Equities research analysts predict that Biodesix, Inc. (NASDAQ:BDSX – Get Rating) will post $6.88 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Biodesix’s earnings, with estimates ranging from $6.60 million to $7.15 million. Biodesix reported sales of $28.87 million during the same quarter last year, which […] ....

United States , Morgan Stanley , Chicago Capital , Zacks Investment Research , Biodesix Inc , Biodesix Company Profile Get Rating , Canaccord Genuity Group , Millennium Management , Get Rating , Investment Research , Genuity Group , Sigma Investments , Two Sigma Advisers , Company Profile , Nodify Lung Nodule Risk Assessment , Nasdaq Bdsx ,

Zacks: Brokerages Anticipate Biodesix, Inc. (NASDAQ:BDSX) Will Post Earnings of -$0.38 Per Share

Equities analysts expect Biodesix, Inc. (NASDAQ:BDSX – Get Rating) to post ($0.38) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Biodesix’s earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.41). Biodesix reported earnings of ($0.23) per […] ....

United States , Geode Capital Management , Goldman Sachs Group Inc , Zacks Investment Research , Biodesix Inc , De Shaw Co , Jpmorgan Chase Co , Biodesix Company Profile Get Rating , Wells Fargo Company , Canaccord Genuity Group , Get Rating , Zacks Investment , Investment Research , Genuity Group , Sachs Group , Capital Management , Wells Fargo , Company Profile , Nasdaq Bdsx ,

-$0.38 Earnings Per Share Expected for Biodesix, Inc. (NASDAQ:BDSX) This Quarter

Equities research analysts expect Biodesix, Inc. (NASDAQ:BDSX – Get Rating) to report earnings per share (EPS) of ($0.38) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Biodesix’s earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.35). Biodesix posted earnings of ($0.23) per share during the same […] ....

United States , Northern Trust Corp , Geode Capital Management , Goldman Sachs Group Inc , Zacks Investment Research , Biodesix Inc , Vanguard Group Inc , Jpmorgan Chase Co , Canaccord Genuity Group , Get Rating , Investment Research , Genuity Group , Capital Management , Trust Corp , Goldman Sachs Group , Sachs Group , Nasdaq Bdsx ,

Biodesix (NASDAQ:BDSX) Rating Lowered to Hold at Zacks Investment Research

Biodesix (NASDAQ:BDSX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The […] ....

United States , Charlesm Watts , Morgan Stanley , Securities Exchange Commission , Chicago Capital , Zacks Investment Research , Biodesix Inc , De Shaw Co , Biodesix Company Profile Get Rating , Wells Fargo Company , Canaccord Genuity Group , Get Rating , Genuity Group , Director Charles , Exchange Commission , Two Sigma Advisers , Company Profile , Nasdaq Bdsx ,

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively

Full-Scale Launch of GeneStrat. | March 14, 2022 ....

Scott Hutton , Biopharma Services , Biodesix Inc , Genscript Inc , Full Year , Pharma Services , Common Stock Purchase Agreement , Nodify Lung , Diagnostic Cortex , Artificial Intelligence , Neutralization Test Kit , Private Securities Litigation Reform Act , Risk Factors , Balance Sheets , Nc Stock Exchange , Press Release , F Bdsx Us09075x1081 ,